Brief: Cortexyme Announces Preclinical Data Demonstrating Efficacy Of Cor803 For The Treatment Of Coronavirus Infections
21/06/2022 14:53
June 21 (Reuters) - Cortexyme Inc CRTX.O :
* CORTEXYME ANNOUNCES PRECLINICAL DATA DEMONSTRATING
EFFICACY OF
COR803 FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
* CORTEXYME INC - PLANS TO EXPLORE PARTNERSHIP AND LICENSING
OPPORTUNITIES TO SUPPORT FUTURE DEVELOPMENT OF COR803
Source text for Eikon: ID:nBw4dn2cYa
Further company coverage: CRTX.O
Recent news on IRulya Therapeutics
See all newsBrief: Quince Therapeutics - Changes Name To Irulya Therapeutics
Brief: Quince Therapeutics - Appoints Brigette Roberts As CEO Effective October 8, 2026
Quince Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Quince Therapeutics Reports Second Quarter 2026 Financial Results And Corporate Update
Quince Therapeutics Q2 net loss widens on acquisition charges